BR122020013811A8 - Aparelho para fornecer um regime de dosagem de proteína plasmática terapêutica - Google Patents

Aparelho para fornecer um regime de dosagem de proteína plasmática terapêutica

Info

Publication number
BR122020013811A8
BR122020013811A8 BR122020013811A BR122020013811A BR122020013811A8 BR 122020013811 A8 BR122020013811 A8 BR 122020013811A8 BR 122020013811 A BR122020013811 A BR 122020013811A BR 122020013811 A BR122020013811 A BR 122020013811A BR 122020013811 A8 BR122020013811 A8 BR 122020013811A8
Authority
BR
Brazil
Prior art keywords
dosing regimen
plasma protein
therapeutic plasma
dosage
pharmacokinetic profile
Prior art date
Application number
BR122020013811A
Other languages
English (en)
Other versions
BR122020013811A2 (pt
Inventor
Loew-Baselli Alexandra
Dickey SPOTTS Gerald
Oh Myungshin
Original Assignee
Baxalta GmbH
Baxalta Inc
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52111779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR122020013811(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta GmbH, Baxalta Inc, Takeda Pharmaceuticals Co filed Critical Baxalta GmbH
Publication of BR122020013811A2 publication Critical patent/BR122020013811A2/pt
Publication of BR122020013811A8 publication Critical patent/BR122020013811A8/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Computing Systems (AREA)
  • Databases & Information Systems (AREA)
  • Physiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioethics (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Probability & Statistics with Applications (AREA)

Abstract

A presente invenção refere-se a um sistema e a um método para prover um regime de dosagem de droga de proteína plasmática terapêutica que incluem determinar um perfil farmacocinético de um paciente usando um modelo Bayesiano de perfis farmacocinéticos de pacientes amostrados. O sistema e o método exemplificativos também incluem determinar um primeiro regime de dosagem para um primeiro intervalo de dosagem específico incluindo (i) uma primeira dosagem e (ii) um primeiro nível de proteína plasmática terapêutica no paciente sobre um período de tempo com base pelo menos no perfil farmacocinético e determinar um segundo regime de dosagem para um segundo intervalo de dosagem específico incluindo (i) uma segunda dosagem e (ii) um segundo nível de proteína plasma terapêutico no paciente sobre o período de tempo com base pelo menos no perfil farmacocinético. O sistema e o método exemplificativos adicionalmente incluem exibir o primeiro regime de dosagem e o segundo regime de dosagem em um dispositivo de cliente de tal modo que o primeiro regime de dosagem seja exibido em conjunção com o segundo regime de dosagem.
BR122020013811A 2013-06-20 2014-06-20 Aparelho para fornecer um regime de dosagem de proteína plasmática terapêutica BR122020013811A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361837421P 2013-06-20 2013-06-20
US201361840969P 2013-06-28 2013-06-28
US201361881214P 2013-09-23 2013-09-23
PCT/US2014/043517 WO2015006033A1 (en) 2013-06-20 2014-06-20 Providing a pharmacokinetic drug dosing regime

Publications (2)

Publication Number Publication Date
BR122020013811A2 BR122020013811A2 (pt) 2017-07-25
BR122020013811A8 true BR122020013811A8 (pt) 2022-08-30

Family

ID=52111779

Family Applications (3)

Application Number Title Priority Date Filing Date
BR122022000127A BR122022000127A8 (pt) 2013-06-20 2014-06-20 Método para fornecer um regime terapêutico de dosagem de proteína plasmática e aparelho que compreende instruções armazenadas no mesmo que são configuradas, quando executadas, para fazer com que o aparelho execute um procedimento para determinar um regime de dosagem
BR112015031856A BR112015031856A8 (pt) 2013-06-20 2014-06-20 Aparelho para prover um regime de dosagem de proteína plasmática terapêutica e dispositivo acessível à máquina
BR122020013811A BR122020013811A8 (pt) 2013-06-20 2014-06-20 Aparelho para fornecer um regime de dosagem de proteína plasmática terapêutica

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR122022000127A BR122022000127A8 (pt) 2013-06-20 2014-06-20 Método para fornecer um regime terapêutico de dosagem de proteína plasmática e aparelho que compreende instruções armazenadas no mesmo que são configuradas, quando executadas, para fazer com que o aparelho execute um procedimento para determinar um regime de dosagem
BR112015031856A BR112015031856A8 (pt) 2013-06-20 2014-06-20 Aparelho para prover um regime de dosagem de proteína plasmática terapêutica e dispositivo acessível à máquina

Country Status (23)

Country Link
US (1) US20140379629A1 (pt)
EP (3) EP3010681B1 (pt)
JP (4) JP2016526542A (pt)
KR (4) KR102296042B1 (pt)
CN (2) CN111508557B (pt)
AU (3) AU2014287706B2 (pt)
BR (3) BR122022000127A8 (pt)
CA (1) CA2915472C (pt)
CL (1) CL2015003641A1 (pt)
EA (1) EA037962B1 (pt)
ES (1) ES2882832T3 (pt)
GE (2) GEP20186882B (pt)
IL (3) IL279313B (pt)
MX (3) MX2015017878A (pt)
MY (2) MY176173A (pt)
NZ (1) NZ715216A (pt)
PH (1) PH12015502800B1 (pt)
PL (1) PL3010681T3 (pt)
SA (2) SA521430246B1 (pt)
SG (1) SG11201510515YA (pt)
UA (1) UA118109C2 (pt)
WO (1) WO2015006033A1 (pt)
ZA (1) ZA201600100B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987321B (zh) * 2011-12-13 2017-06-09 皇家飞利浦有限公司 用于基于结果质量的剂量优化的系统和方法
KR102370479B1 (ko) 2012-10-05 2022-03-04 다이앤 몰드 수학적 모형 함수로서의 환자-특이적 투여법용 의약
ES2967617T3 (es) * 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
WO2015154090A1 (en) 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
US11062797B2 (en) * 2014-10-10 2021-07-13 Continuous Precision Medicine Method and system for obtaining and using pharmacokinetic data in drug administration
SG10202009369SA (en) * 2015-04-09 2020-10-29 Diane Mould Systems and methods for patient-specific dosing
WO2017136583A1 (en) * 2016-02-02 2017-08-10 Versartis, Inc. Growth hormone treatment adherence system
CA3020346A1 (en) * 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regimen
JP6807015B2 (ja) * 2016-06-13 2021-01-06 ソニー株式会社 情報処理装置、情報処理方法、およびプログラム
US10896749B2 (en) * 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
US20190365317A1 (en) * 2017-02-01 2019-12-05 Shire Human Genetic Therapies, Inc. Physiological sensing and therapeutic administration system and method
BE1027052A1 (fr) 2019-02-14 2020-09-07 Aardex Group Procede d'assistance a la prise ou a l'acte d'un traitement therapeutique
US10970651B1 (en) * 2019-12-02 2021-04-06 Sas Institute Inc. Analytic system for two-stage interactive graphical model selection
KR102420872B1 (ko) * 2020-12-18 2022-07-14 포항공과대학교 산학협력단 강화학습과 약동-약력학 모델을 이용한 연속 약물 투여량 결정 방법
CN113053508A (zh) * 2021-03-29 2021-06-29 深圳市科曼医疗设备有限公司 基于触控屏的交互控制方法及装置

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07124125A (ja) * 1993-11-04 1995-05-16 S R L:Kk 薬物投与解析システム
HUP9700603A3 (en) * 1996-03-20 2001-08-28 Baxter Ag Pharmaceutical preparation for the treatment of blood coagulation disorders
AU5219798A (en) * 1996-12-09 1998-07-03 Samuel David Gpi-ceruloplasmin, analogs thereof, and methods of use
BR0010316A (pt) * 1999-05-11 2004-04-27 Ortho Mcnell Pharmaceutical In Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente
US7860583B2 (en) * 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
JP2004510961A (ja) * 2000-09-15 2004-04-08 ビルコ・ビーブイビーエイ 疾患の処置のための薬物療法を最適化するシステムおよび方法
AU2004209286B2 (en) * 2003-02-01 2009-01-08 Baxter International Inc. Wireless medical data communication system and method
EP1642607A1 (en) * 2004-10-04 2006-04-05 Sanofi-Aventis Deutschland GmbH Dose display mechanism for a drug delivery device
JP2006155071A (ja) * 2004-11-26 2006-06-15 Toshiba Sumiden Medical Information Systems Corp 電子カルテ薬物療法指示実施システム
US20060183786A1 (en) * 2005-02-16 2006-08-17 Chi Mei Foundation Hospital Injectable long-acting analgesic composition comprising an ester derivative of ketorolac
CA2911569C (en) * 2005-11-29 2019-11-26 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
EP2286359A2 (en) * 2008-03-27 2011-02-23 Medtronic, Inc. Method and system to define patient specific therapeutic regimens by means of pharmacokinetic and pharmacodynamic tools
US8591454B2 (en) * 2008-11-10 2013-11-26 The Invention Science Fund I, Llc Administering a therapeutic agent with more than one taggant
SG181130A1 (en) 2009-12-06 2012-07-30 Biogen Idec Hemophilia Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof

Also Published As

Publication number Publication date
EP3309696A1 (en) 2018-04-18
AU2014287706B2 (en) 2017-10-05
MX2023000359A (es) 2023-02-13
KR20220065097A (ko) 2022-05-19
JP7060291B2 (ja) 2022-04-26
EA037962B1 (ru) 2021-06-16
JP2021061012A (ja) 2021-04-15
JP2022105022A (ja) 2022-07-12
MX2015017878A (es) 2016-09-14
IL243208A0 (en) 2016-02-29
CA2915472A1 (en) 2015-01-15
MX2020004112A (es) 2020-07-24
IL243208B (en) 2020-06-30
AU2017272293A1 (en) 2018-01-04
JP2019196352A (ja) 2019-11-14
BR112015031856A2 (pt) 2017-07-25
CN111508557A (zh) 2020-08-07
NZ715216A (en) 2020-07-31
EP3010681B1 (en) 2021-05-19
SA515370289B1 (ar) 2022-02-02
EA201690048A1 (ru) 2016-05-31
CA2915472C (en) 2023-09-19
AU2020202664A1 (en) 2020-05-14
ES2882832T3 (es) 2021-12-02
PH12015502800A1 (en) 2016-03-14
EP3879534A1 (en) 2021-09-15
GEP20196990B (en) 2019-07-10
AU2014287706A1 (en) 2016-01-21
MY176173A (en) 2020-07-24
EP3010681A4 (en) 2017-03-08
WO2015006033A1 (en) 2015-01-15
CN105592973B (zh) 2020-06-19
KR20160022874A (ko) 2016-03-02
ZA201600100B (en) 2019-09-25
CL2015003641A1 (es) 2016-10-28
JP2016526542A (ja) 2016-09-05
SA521430246B1 (ar) 2022-09-14
IL274848A (en) 2020-07-30
BR122020013811A2 (pt) 2017-07-25
PL3010681T3 (pl) 2021-11-15
KR102352133B1 (ko) 2022-01-18
JP6813237B2 (ja) 2021-01-13
KR102296042B1 (ko) 2021-08-31
CN105592973A (zh) 2016-05-18
IL279313A (en) 2021-01-31
BR122022000127A8 (pt) 2022-08-30
GEP20186882B (en) 2018-07-25
IL279313B (en) 2022-08-01
PH12015502800B1 (en) 2016-03-14
BR122022000127A2 (pt) 2017-07-25
US20140379629A1 (en) 2014-12-25
KR20220011217A (ko) 2022-01-27
SG11201510515YA (en) 2016-01-28
UA118109C2 (uk) 2018-11-26
BR112015031856A8 (pt) 2022-08-30
AU2020202664B2 (en) 2022-06-02
EP3010681A1 (en) 2016-04-27
KR20210110736A (ko) 2021-09-08
JP7398031B2 (ja) 2023-12-14
CN111508557B (zh) 2024-03-26
AU2017272293B2 (en) 2020-01-23
KR102397974B1 (ko) 2022-05-13
MY195911A (en) 2023-02-27

Similar Documents

Publication Publication Date Title
BR122020013811A8 (pt) Aparelho para fornecer um regime de dosagem de proteína plasmática terapêutica
BR112014019386A8 (pt) Dispositivo suplementar para a fixação a um dispositivo de injeção
BR112014018924A8 (pt) Método de gerar uma etiqueta de dosagem customizada para um dispositivo de distribuição de medicamento
MX2014009038A (es) Equipo de combinacion de dosis de seguridad y jeringa de seguridad.
BR112013033943A2 (pt) sistema para uso com uma ou mais fontes de dados filiados de paciente, métodos para atualizar um conjunto de dados de orientação específico de paciente, atualizar uma pluralidade de bancos de dados de dispositivos de interface de paciente, operar um dispositivo de interface de paciente, administrar dados em um sistema, e, dispositivo de interface de paciente
BR112018011803A2 (pt) método e mecanismo para a administração de gases incluindo óxido nítrico
SG10201804607RA (en) System and method for facilitating delivery of patient-care
DK3193981T3 (da) Medikamentadministrationsanordning i form af voluminøst hudplaster med integreret mekanisme til hudsterilisering af injektionssted
BR112014028600A8 (pt) Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
BR112016006188A2 (pt) método de tratamento com um protocolo de fármaco e um sistema com uma base de dados relacional acoplado a um ou mais dispositivos eletrônicos ; sistema para a gestão de um tratamento medicamentoso pela administração de um fármaco a um paciente e método de gestão de um tratamento com drogas usando um sistema de informação com uma base de dados relacional.
IN2015DN03826A (pt)
BR112015004943A2 (pt) sistema de software de informações do paciente que inclui mapa de infusão
BR112012020270A2 (pt) sistema e método para administrar medicamentos com base em valores de urina.
MX2018013503A (es) Aparatos, métodos y sistemas para administrar medicamento utilizando kits de medicamento.
CL2016000641A1 (es) Un controlador para un dispositivo para administrar un medio de contraste que comprende un agente de contraste radiológico en un paciente usando un inyector, y método para determinar el volumen óptimo de un medio de contraste que comprende un agente de contraste radiológico que ha de administrarse en un paciente, antes de la administración.
MX2017008000A (es) Sistema de inyeccion de un solo uso.
MX2016000103A (es) Dispositivo de administracion de farmaco oral y metodos de uso del mismo.
BR112017022984A2 (pt) dispositivo para facilitar o posicionamento de um cateter para administrar um medicamento em um paciente que esteja respirando espontaneamente
BR112018016287A2 (pt) sistema de perfusão, método para administrar diretamente a um paciente em necessidade do mesmo uma dose de um fármaco antineoplásico e recipiente de perfusão
EA202190596A2 (ru) Предоставление фармакокинетической схемы дозирования лекарственного средства
Lawton et al. Spoonful of sugar: Improving the palatability of emergency department visits for children and their families.
TH160649B (th) เครื่องและวิธีการสำหรับข้อกำหนดการให้ขนาดยาทางเภสัชจลนศาสตร์
TH160649A (th) เครื่องและวิธีการสำหรับข้อกำหนดการให้ขนาดยาทางเภสัชจลนศาสตร์
林彤 et al. Clinical Outcome of in Vitro Fertilization-embryo Transfer in Patients Over 40 Years from a Single Institution in Guangdong, China
Friese Staff and student satisfaction with Alberta student pharmacists administering vaccination in the University of Alberta annual influenza campaign

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: B23P 17/04 , A61M 5/31

Ipc: G16H 20/17 (2006.01), G06N 7/00 (2006.01), A61P 7/

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]